a transcription factor of the forkhead family. A central regulator of metabolism in several cell types. May play an important role in myogenic growth and differentiation, and in the regulation of lipolysis in adipocytes by controlling the expression of adipose triglyceride lipase (ATGL), the rate-limiting lipolytic enzyme. Translocation of this gene with PAX3 has been associated with alveolar rhabdomyosarcoma. Contains 1 fork-head domain. Note: This description may include information from UniProtKB.
Protein type: DNA binding protein; Transcription factor; Nuclear receptor co-regulator
Cellular Component: cytoplasm; nucleus; cytosol
Molecular Function: protein binding; DNA binding; protein phosphatase 2A binding; sequence-specific DNA binding; ubiquitin protein ligase binding; DNA bending activity; protein kinase binding; transcription factor activity
Biological Process: transcription from RNA polymerase II promoter; tissue development; positive regulation of apoptosis; apoptosis; positive regulation of transcription, DNA-dependent; negative regulation of transcription from RNA polymerase II promoter; glucose homeostasis; positive regulation of gluconeogenesis; regulation of transcription, DNA-dependent; organ development; positive regulation of autophagy; blood vessel development; transcription, DNA-dependent; cellular response to starvation; negative regulation of stress-activated MAPK cascade; negative regulation of fat cell differentiation; pattern specification process; regulation of cell proliferation; regulation of transcription from RNA polymerase II promoter; embryonic development; cellular response to insulin stimulus; positive regulation of protein catabolic process; insulin receptor signaling pathway; positive regulation of transcription from RNA polymerase II promoter; response to DNA damage stimulus; negative regulation of apoptosis
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.